Neurologia最新文献

{"title":"Normative data for the Reading the Mind in the Eyes Test in a Spanish adult population","authors":"C. Pérez-Enríquez,&nbsp;G. García-Escobar,&nbsp;M.P. Fernández-Lozano,&nbsp;R.M. Manero,&nbsp;J. Peña-Casanova,&nbsp;G. Sánchez-Benavides","doi":"10.1016/j.nrleng.2026.502080","DOIUrl":"10.1016/j.nrleng.2026.502080","url":null,"abstract":"<div><h3>Objective</h3><div>The present study aims to provide Spanish normative data for the Reading the Mind in the Eyes Test (RMET) in a Spanish adult population.</div></div><div><h3>Method</h3><div>The normative sample consisted of 167 subjects aged between 20 and 94 years. The main sociodemographic variables (age, education level, and sex) were analysed, and raw scores were transformed into age-adjusted scaled scores, with the corresponding adjustments when a significant influence was found.</div></div><div><h3>Results</h3><div>Age had a negative effect on test performance in the oldest age group (≥ 50 years), whereas education level had a positive effect on test performance in both age groups; furthermore, women performed better than men. Education level (r² = 0.226 in the &lt; 50 years group; r² = 0.237 in the ≥ 50 years group) and sex (r² = 0.260 in the &lt; 50 years group; r² = 0.287 in the ≥ 50 years group) had a greater influence on test performance than age (r² = 0.000 in the &lt; 50 years group; r² = 0.084 in the ≥ 50 years group).</div></div><div><h3>Conclusion</h3><div>The normative data provided may be useful to improve the representativeness of RMET performance in young and older adults from the Spanish population.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502080"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between anti-Zic4 antibodies and sensory neuronopathy in small-cell lung cancer","authors":"I. Ros González,&nbsp;A. Chavarría-Miranda,&nbsp;C. González Folgueral,&nbsp;M. Pedraza Hueso","doi":"10.1016/j.nrleng.2026.502073","DOIUrl":"10.1016/j.nrleng.2026.502073","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502073"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148045307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric oxygen therapy as a therapeutic option for post-COVID syndrome fatigue","authors":"D.A. García Estévez","doi":"10.1016/j.nrleng.2026.502029","DOIUrl":"10.1016/j.nrleng.2026.502029","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502029"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to access to anti-CGRP monoclonal antibodies in Spain: survey of neurologists, hospital pharmacists, and patients","authors":"P. Irimia,&nbsp;P. Díaz-Ruiz,&nbsp;I. Colomina,&nbsp;R. Belvís,&nbsp;J.M. Lainez","doi":"10.1016/j.nrleng.2026.502081","DOIUrl":"10.1016/j.nrleng.2026.502081","url":null,"abstract":"<div><h3>Introduction</h3><div>Neurologists, hospital pharmacists (HP), and patients advocate for improved access to anti-CGRP monoclonal antibodies (mAbs) in migraine prophylaxis.</div></div><div><h3>Objectives</h3><div>To identify the barriers to access to anti-CGRP mAbs in Spain and to propose potential solutions.</div></div><div><h3>Material and methods</h3><div>Cross-sectional study with online surveys aimed at neurologists, HPs, and patients. Descriptive statistics were used to analyse the data. Categorical variables were expressed in terms of frequency and percentage.</div></div><div><h3>Results</h3><div>A total of 55.1% of neurologists and 67.4% of HPs reported that at their hospitals, the criteria of the therapeutic positioning statement (TPS) were followed on a case-by-case basis to authorise the dispensing of anti-CGRP mAbs. However, more than 30% of neurologists and HPs reported that they had their own protocols. A total of 62.8% of neurologists and 23.3% of HPs disagreed with some TPS criteria and, according to 41.9% of pharmacists, not all neurologists at their hospital were able to prescribe anti-CGRP mAbs. Neurologists and HPs considered that the TPS criteria should be reviewed periodically. Some 32.9% of patients considered access to a migraine specialist to have been difficult. A total of 88.4% of neurologists and 81.4% of HPs thought that referral from primary care to a specialised consultation should be faster.</div></div><div><h3>Conclusions</h3><div>The main barriers to accessing anti-CGRP mAbs are the difficulty of accessing a neurology specialist, and the strict TPS criteria and differences in their application between autonomous communities and hospitals. Neurology referral systems should be improved and TPS criteria reviewed.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502081"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADAM10 and its role in Alzheimer disease","authors":"P. Agüero,&nbsp;E. Gómez Tortosa","doi":"10.1016/j.nrleng.2026.502083","DOIUrl":"10.1016/j.nrleng.2026.502083","url":null,"abstract":"<div><h3>Introduction</h3><div>The amyloidogenic pathway of amyloid precursor protein (APP) processing is well known in the pathogenesis and therapeutics of Alzheimer disease (AD), whereas the non-amyloidogenic pathway has been less studied. ADAM10 is the main α-secretase responsible for this pathway in the human brain.</div></div><div><h3>Content</h3><div>ADAM10 belongs to a family of transmembrane proteins with catalytic activity. It acts as an α-secretase on APP and many other substrates, some of which are particularly relevant in the central nervous system. The <em>ADAM10</em> gene has been identified in genome-wide association studies of patients with AD; mutations have been reported in families with strong functional support but incomplete segregation; and haploinsufficiency has been reported in a family carrying a nonsense mutation. However, genetic studies of AD cohorts have not identified causal variants. ADAM10 levels in biological fluids show conflicting results, except in platelets, where patients with AD consistently exhibit reduced levels. Stimulation of ADAM10 as a therapeutic target offers new opportunities through various components and such measures as physical exercise. However, only one (positive) clinical trial has been published to date, using the retinoid acitretin.</div></div><div><h3>Conclusions</h3><div>ADAM10 plays a fundamental role in brain function, and sufficient studies support its involvement in AD pathogenesis. There are only isolated examples of <em>ADAM10</em> mutations as a genetic cause, but these encourage continued screening in familial AD. ADAM10 levels in platelets could be considered as a biomarker. The enhancement of ADAM10 expression in AD remains a therapeutic target that requires further research.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502083"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriate use recommendations of the Spanish Society of Neurology’s Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease","authors":"R. Sánchez-Valle,&nbsp;D. Alcolea,&nbsp;G. Amer Ferrer,&nbsp;M. Balasa,&nbsp;I. Casado Naranjo,&nbsp;J. Fortea,&nbsp;A. Lladó,&nbsp;A. Lleó,&nbsp;A.M. Montes,&nbsp;L. Martinez Lozano,&nbsp;P. Martínez-Lage,&nbsp;J.A. Matias-Guiu,&nbsp;M. Mendioroz,&nbsp;D.A. Perez Martinez,&nbsp;G.P. Ripoll,&nbsp;M. Riverol,&nbsp;P. Sanchez-Juan,&nbsp;H.V. Bondía,&nbsp;on behalf of the Spanish Society of Neurology’s Behavioural Neurology, Dementia Study Group working group for the appropriate use of anti-amyloid monoclonal antibody treatment","doi":"10.1016/j.nrleng.2026.502075","DOIUrl":"10.1016/j.nrleng.2026.502075","url":null,"abstract":"<div><h3>Introduction</h3><div>Two anti-amyloid monoclonal antibodies (mAb) have recently been approved by the European Commission for the treatment of Alzheimer disease (AD). In this context, the Spanish Society of Neurology’s Behavioural Neurology and Dementia Study Group decided to issue a consensus statement gathering the recommendations of national experts on the appropriate use of anti-amyloid mAb. The document provides recommendations on practical aspects of the use of these drugs in Spain, which are intended to complement the indications described by regulators.</div></div><div><h3>Development</h3><div>Fifty-seven members of the study group participated in the consensus process (January-September 2025), which includes recommendations on criteria for selecting candidates, adverse reactions, monitoring, criteria for suspension of treatment, shared physician-patient decision-making, and requirements of prescribing centres. All participants were invited to revise the complete document, specifically asked whether they agreed with the content of each section, and invited to share their comments.</div></div><div><h3>Conclusions</h3><div>The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of AD, but is not free of challenges. The participating experts showed a high level of consensus on basic clinical and practical considerations, with the requirements of prescribing centres and criteria for treatment suspension being the areas that generated the most debate. Participants noted concerns about equity of access and implementation into current care, particularly if insufficient resources are allocated to this implementation. This document will require updates in line with new knowledge and/or approval of new drugs in this class.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502075"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148045365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarifications to “Isolated bilateral facial palsy as the initial presenting manifestation of generalized myasthenia gravis preceding myasthenic crisis”: the importance of not forgetting single-fiber electromyography","authors":"M. León-Ruiz,&nbsp;R. Ghosh,&nbsp;K. Bole,&nbsp;S. Dubey,&nbsp;J. Benito-León","doi":"10.1016/j.nrleng.2026.502027","DOIUrl":"10.1016/j.nrleng.2026.502027","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502027"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy for disabling tremor secondary to multiple sclerosis","authors":"Á. Menéndez,&nbsp;L. Ispierto,&nbsp;M. Tardáguila,&nbsp;C. Ramo-Tello,&nbsp;A. Gonzalez,&nbsp;J. Muñoz,&nbsp;R. Álvarez,&nbsp;D. Vilas","doi":"10.1016/j.nrleng.2026.502034","DOIUrl":"10.1016/j.nrleng.2026.502034","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502034"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sulcal artery syndrome: an unusual cause of spinal ischaemia in a patient with persistent trigeminal artery as probable predisposing factor","authors":"C.M. Sánchez García,&nbsp;Á. Valero López,&nbsp;R. Hernández Clares,&nbsp;F.A. Martínez García","doi":"10.1016/j.nrleng.2026.502086","DOIUrl":"10.1016/j.nrleng.2026.502086","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502086"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of insomnia in the neurology consultation of a multidisciplinary sleep unit","authors":"M.J. Abenza Abildúa,&nbsp;E. Suárez Gisbert,&nbsp;F.J. Navacerrada Barrero,&nbsp;V. Lores Gutiérrez,&nbsp;D. Rojano Baz,&nbsp;Á. Díaz Pérez,&nbsp;Á. Gómez de la Riva,&nbsp;A. Miralles Martínez","doi":"10.1016/j.nrleng.2026.502082","DOIUrl":"10.1016/j.nrleng.2026.502082","url":null,"abstract":"<div><h3>Introduction</h3><div>This study analyses the most common types of insomnia and comorbidities in patients referred to our sleep unit’s neurology consultation, and how these patients are managed.</div></div><div><h3>Material and methods</h3><div>We conducted a retrospective, observational, descriptive study of consecutive patients diagnosed with insomnia at our hospital’s sleep unit between January and December 2023, inclusive.</div></div><div><h3>Results</h3><div>Of the 200 patients registered in 2023, 127 (63.5%) were diagnosed with insomnia. Of these, 64 were women (50.39%) and 63 were men (49.60%), with a mean age of 53.24 years (SD: 15.372). In our sample, the main aetiology or associated comorbidity of insomnia according to the American Academy of Sleep Medicine classification (insomnia associated with mental illness, medical illness, and other sleep disorders) was as follows: 77 patients (60.62%) with active mental disorder at the time of the consultation (anxiety, dysthymia, depression, hyperalertness/stress/rumination) and 30 patients with insomnia associated with a medical illness. The following sleep comorbidities were observed: periodic leg movements (n = 9), restless legs syndrome (n = 15), and obstructive sleep apnoea (n = 45). Of the 31 patients with insomnia associated with medical disorders, 16 also presented reactive anxiety/depression that contributed to the persistence or worsening of insomnia. Of the total 127 patients, 77 patients had insomnia associated with a mental condition, and 16 had insomnia secondary to both medical and mental conditions (73.22%).</div></div><div><h3>Conclusions</h3><div>Insomnia associated with mental conditions (depression, anxiety, dysthymia) is the most common type of insomnia. Its prevalence has increased since the COVID-19 pandemic, and now accounts for two-thirds of the patients assessed at the neurology consultations of sleep units. Idiopathic insomnia accounts for barely one-tenth of cases. Patients with chronic insomnia would benefit from initial assessment by mental health professionals, who are able to diagnose the most prevalent comorbidities and triggers, as well as other disorders that are frequently overlooked by other professionals. This approach would also improve the identification of patients eligible for cognitive-behavioral therapy, the first line of treatment for insomnia according to clinical guidelines, ultimately improving patient care and healthcare resource management.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"41 8","pages":"Article 502082"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}